Matulonis Ursula A, Seiden Michael V, Roche Maria, Krasner Carolyn, Fuller Arlan F, Atkinson Tina, Kornblith Alice, Penson Richard
Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
J Pain Symptom Manage. 2005 Dec;30(6):563-9. doi: 10.1016/j.jpainsymman.2005.05.018.
Symptoms of malignant bowel obstruction in patients with recurrent ovarian cancer lead to a poor quality of life. Sandostatin LAR Depot (LAR) is an intramuscular, monthly administered, long-acting form of octreotide. LAR's safety and utility were evaluated in a pilot study enrolling 15 advanced ovarian cancer patients with bowel dysfunction. Once safety with subcutaneous (SQ) octreotide was assessed, patients were given 30 mg LAR on Day 1 and octreotide SQ for 2 weeks. Of 13 evaluable patients, three patients had a major response to LAR treatment with reduction in bowel obstruction symptoms, two had a minor response, four had no response, and four had progressive symptoms. Three patients remained on LAR for more than 9 months. No significant toxicities were attributable to octreotide or LAR. Because three patients received nine or more monthly injections of LAR, possible direct antitumor effects of LAR or synergy with chemotherapy needs to be explored.
复发性卵巢癌患者发生恶性肠梗阻的症状会导致生活质量下降。善龙长效注射剂（LAR）是一种每月肌肉注射一次的长效奥曲肽制剂。在一项纳入15例患有肠道功能障碍的晚期卵巢癌患者的试点研究中，对善龙长效注射剂的安全性和效用进行了评估。在评估皮下注射（SQ）奥曲肽的安全性后，患者在第1天接受30mg善龙长效注射剂治疗，并皮下注射奥曲肽2周。在13例可评估的患者中，3例患者对善龙长效注射剂治疗有显著反应，肠梗阻症状减轻，2例有轻微反应，4例无反应，4例症状进展。3例患者使用善龙长效注射剂超过9个月。未发现奥曲肽或善龙长效注射剂有明显毒性。由于3例患者接受了9次或更多次每月一次的善龙长效注射剂注射，因此需要探索善龙长效注射剂可能的直接抗肿瘤作用或与化疗的协同作用。
